Identification of high risk coronary lesions, plaque rupture, early myocardial ischemia and in-stent restenosis (ISR) remains a clinical challenge. We employed proteomic, lipidomic and traditional approaches to identify novel biomarkers.
TMEM198 was identified as a marker of plaque rupture. 42 proteins and multiple lipids identified early myocardial ischemia. 12 proteins and 2 lipids identified ISR. Phospholipase A2 was associated with periprocedural ischemia.
Combined, these experiments utilise unbiased methodologies for novel cardiac biomarker discovery.